Format

Send to

Choose Destination
Neurology. 2015 Apr 14;84(15):1582-91. doi: 10.1212/WNL.0000000000001462. Epub 2015 Mar 20.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.

Author information

1
From the Department of Neurology (L.K.), University Hospital, Basel, Switzerland; St. Michael's Hospital (P.O.'C.), Toronto, Canada; Medical Image Analysis Centre (E.-W.R.), University Hospital, University of Basel, Switzerland; Department of Neurology (C.P.), VU University Medical Center, Amsterdam, Netherlands; Ludwig-Maximilians University of Munich and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Germany; Department of Neurology (K.S.), Medical University of Lodz, Poland; Novartis Pharmaceuticals Corporation (S.R., G.F.), East Hanover, NJ; and Novartis Pharma AG (R.S., P.v.R., L.Z.-A.), Basel, Switzerland. lkappos@uhbs.ch.
2
From the Department of Neurology (L.K.), University Hospital, Basel, Switzerland; St. Michael's Hospital (P.O.'C.), Toronto, Canada; Medical Image Analysis Centre (E.-W.R.), University Hospital, University of Basel, Switzerland; Department of Neurology (C.P.), VU University Medical Center, Amsterdam, Netherlands; Ludwig-Maximilians University of Munich and Munich Cluster for Systems Neurology (SyNergy) (R.H.), Germany; Department of Neurology (K.S.), Medical University of Lodz, Poland; Novartis Pharmaceuticals Corporation (S.R., G.F.), East Hanover, NJ; and Novartis Pharma AG (R.S., P.v.R., L.Z.-A.), Basel, Switzerland.

Abstract

OBJECTIVE:

To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS).

METHODS:

Patients completing FTY720 Research Evaluating Effects of Daily Oral Therapy in MS (FREEDOMS) were eligible for this dose-blinded, parallel-group extension study, continuing fingolimod 0.5 mg/day or 1.25 mg/day, or switching from placebo to either dose, randomized 1:1. Efficacy variables included annualized relapse rate (ARR), brain volume loss (BVL), and confirmed disability progression (CDP). Between-group analyses were conducted in the intent-to-treat (ITT) population from FREEDOMS baseline to end of study. Within-group analyses compared years 0-2 (FREEDOMS) and years 2-4 (extension) in the extension ITT population.

RESULTS:

Of 1,272 patients (FREEDOMS ITT population), 1,033 were eligible, and 920 enrolled in the extension study (continuous-fingolimod: 0.5 mg [n = 331], 1.25 mg [n = 289]; placebo-fingolimod: 0.5 mg [n = 155], 1.25 mg [n = 145]); 916 formed the extension ITT population (n = 330; n = 287; n = 154; n = 145) and 773 (84%) completed. In the continuous-fingolimod groups, ARR was lower (p < 0.0001), BVL was reduced (p < 0.05), and proportionately more patients were free from 3-month CDP (p < 0.05) than in a group comprising all placebo-fingolimod patients. Within each placebo-fingolimod group, ARR was lower (p < 0.001, both) and BVL was reduced after switching (p < 0.01, placebo-fingolimod 0.5 mg). Rates and types of adverse events were similar across groups; no new safety issues were reported.

CONCLUSION:

Efficacy benefits of fingolimod during FREEDOMS were sustained during the extension; ARR and BVL were reduced after switching.

CLASSIFICATION OF EVIDENCE:

This study provides Class IV evidence that long-term fingolimod treatment is well-tolerated and reduces relapse rates, disability progression, and MRI effects in patients with RRMS.

PMID:
25795646
PMCID:
PMC4408283
DOI:
10.1212/WNL.0000000000001462
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center